



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: ☒ HIV-1 M46I/L63P/V82T/I84V Virus

Catalog Number: 2841

Lot Number: 3/6/95

Release Category: E

Provided: 1 ml cell-free virus

Original Source: Mutations in the protease gene were constructed by gapped-duplex oligonucleotide mutagenesis of a pWT-6 subclone. Infectious proviral clones were generated by subcloning the 833 bp *Apa*I-Sse83871 fragment into pNL4-3. This clone was used to transfect HeLa cells, and virus stocks were generated by coculture with H9 cells.

Host Strain: H9 and MT-4 cells

Propagation: RPMI 1640, 90%; fetal bovine serum, 10%.

Sterility: Negative for bacteria, fungi, and mycoplasma.

Description: R5X4.

Special Characteristics: Resistant to the structurally diverse protease inhibitors MK-639, XM323, A-80987, Ro 31-8959, VX-478, and SC-52151. The resistance profile is identical to those of both HIV-1 L10R/M46I/L63P/V82T/I84V Virus (Catalog #2840) and a patient isolate obtained after 40 weeks of treatment with MK-639 alone.

Recommended Storage: Liquid nitrogen.

Contributor: Dr. Emilio Emini.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutssch PJ, Emini EA. *In vivo* emergence of HIV-1 variants resistant to multiple protease inhibitors. *Nature* **374**:569-571, 1995.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 M46I/L63P/V82T/I84V Virus from Dr. Emilio Emini." Also include the references cited above in any publications.

Recipient must not use or incorporate the reagent for commercial purposes.

Last Updated: July 31, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.